

| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 10mg | 360 pills | €1.12 | €447.73 €402.96 Best Price | |
| 10mg | 180 pills | €1.18 | €235.21 €211.69 | |
| 10mg | 120 pills | €1.20 | €160.59 €144.53 | |
| 10mg | 90 pills | €1.26 | €124.90 €112.41 | |
| 10mg | 60 pills | €1.31 | €87.59 €78.83 | |
| 10mg | 30 pills | €1.50 | €50.27 €45.25 | |
| 20mg | 360 pills | €1.68 | €673.23 €605.91 | |
| 20mg | 240 pills | €1.71 | €455.84 €410.26 | |
| 20mg | 180 pills | €1.72 | €345.53 €310.98 | |
| 20mg | 120 pills | €1.75 | €233.59 €210.23 | |
| 20mg | 90 pills | €1.80 | €180.06 €162.05 | |
| 20mg | 60 pills | €1.83 | €123.28 €110.95 | |
| 20mg | 30 pills | €1.87 | €63.25 €56.93 | |
| 30mg | 240 pills | €2.58 | €689.45 €620.51 | |
| 30mg | 180 pills | €2.61 | €522.36 €470.12 | |
| 30mg | 120 pills | €2.64 | €352.02 €316.82 | |
| 30mg | 90 pills | €2.67 | €267.66 €240.89 | |
| 30mg | 60 pills | €2.73 | €181.68 €163.51 | |
| 30mg | 30 pills | €2.92 | €97.32 €87.59 | |
| 40mg | 180 pills | €3.46 | €691.07 €621.97 Popular | |
| 40mg | 120 pills | €3.58 | €476.93 €429.24 | |
| 40mg | 90 pills | €3.61 | €360.13 €324.12 | |
| 40mg | 60 pills | €3.65 | €243.33 €218.99 | |
| 40mg | 30 pills | €3.80 | €126.52 €113.87 |
Disclaimer: This information supports, but does not replace, professional medical advice. Paxil is paroxetine, a selective serotonin reuptake inhibitor (SSRI) used to treat certain mood and anxiety disorders; consult a healthcare professional for individual advice.
Paxil is paroxetine, a selective serotonin reuptake inhibitor (SSRI) that modulates brain serotonin levels. This pharmacologic action is intended to help rebalance mood and anxiety-related circuitry.
The SSRI class operates by blocking the serotonin transporter, leading to increased serotonin availability in synapses. This mechanism underpins symptomatic relief for multiple depressive and anxiety disorders.
Paxil is prescribed as part of a treatment plan that may include psychotherapy. It is not a cure, and response varies among individuals. In Ireland, prescribing decisions consider diagnostic criteria, patient history, and potential drug interactions.
The medicine is available in multiple tablet formulations, including standard tablets and orally disintegrating tablets, to accommodate patient preference and swallowing ability. Use must follow the instructions supplied by the pharmacist or prescriber, and changes should only occur under professional guidance.
Discontinuation should be undertaken gradually under medical supervision to minimise withdrawal or relapse risk. If stopping unexpectedly, seek prompt medical advice to adjust therapy safely.
This section provides foundational information to support informed discussion with a prescriber or pharmacist in Ireland.
Paxil has established indications for depressive disorders and several anxiety-related conditions. In clinical practice, it may be chosen for major depressive disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive–compulsive disorder, and post-traumatic stress disorder, subject to local approvals and guidelines.
When selecting therapy, clinicians weigh symptom profile, prior response to antidepressants, comorbidities, and safety considerations. Paxil may be preferred when anxiety symptoms are prominent alongside mood disturbance, or when a patient has previously shown a favorable response to paroxetine.
Comparisons with alternative antidepressants guide decision-making. Some patients may benefit from a different SSRI or from a serotonin–norepinephrine reuptake inhibitor (SNRI) based on side effect profiles, tolerability, and drug interaction risk. Psychotherapy, lifestyle factors, and comorbid conditions are considered alongside pharmacotherapy.
In pregnancy planning or lactation, or in elderly patients, dosing strategies and risk–benefit assessments differ. The official patient leaflet and local clinical guidelines should be consulted, and advice from a prescriber or pharmacist obtained before initiating or changing therapy.
A comprehensive evaluation by the prescriber informs whether Paxil is the most appropriate option among available antidepressants for a given condition. If access to therapy is limited, or if intolerance or interactions arise, alternate agents or non-pharmacologic strategies may be explored with professional guidance.
Paroxetine acts as a selective inhibitor of the serotonin transporter (SERT), increasing serotonin concentrations in synaptic spaces. This pharmacologic effect is the primary driver of symptom improvement in many patients with depressive or anxiety-related disorders.
Compared with some other SSRIs, paroxetine may exhibit a higher affinity for SERT and relatively less activity on other transporter targets. This distinction can influence both therapeutic outcomes and the spectrum of adverse effects, including anticholinergic properties that may contribute to certain tolerability differences.
Pharmacokinetic characteristics also differ among SSRIs. Paroxetine has a shorter elimination half-life than fluoxetine, which can affect withdrawal phenomena if treatment is stopped abruptly. This pharmacokinetic profile informs planning around discontinuation or dose adjustments under supervision.
In clinical practice, these pharmacologic and kinetic distinctions translate into practical considerations, such as initial tolerability, time to improvement, and the likelihood of discontinuation symptoms during tapering. Individual responses vary, and treatment choices are tailored by the prescriber in collaboration with the patient.
| Name | Primary use | Typical onset of benefit | Key advantage |
|---|---|---|---|
| Paxil (paroxetine) | Major depressive disorder; anxiety disorders; OCD; PTSD | Symptom improvement usually begins after several weeks, with gradual ongoing benefit | Strong efficacy for anxiety symptoms in some patients; familiar tolerability in those with prior response |
| Sertraline (Zoloft) | Depression; PTSD; social anxiety; OCD; panic disorder | Often noticeable improvement within a few weeks; full effect may take longer | Generally well tolerated with broad indication coverage and robust evidence base |
| Escitalopram (Lexapro) | Depression; generalized anxiety disorder; social anxiety | Early symptom relief can occur within weeks; full response may require several weeks | Typically well tolerated with a favorable tolerability profile |
| Fluoxetine (Prozac) | Depression; OCD; panic disorder; bulimia nervosa | Benefit often observed within a few weeks; long-acting formulation may offer convenience | Long half-life reduces discontinuation effects and supports gradual tapering |
When considering these options, clinicians weigh the risk of adverse effects, potential interactions, and patient preferences. Some patients may experience better tolerability with one agent over another, or may respond more robustly to a particular antidepressant class. A prescriber can tailor therapy based on clinical history and current health status.
Irish practice guidelines emphasise careful assessment, monitoring for adverse effects, and shared decision-making with the patient. If a change of therapy is being considered, a plan for monitoring symptoms and potential withdrawal phenomena should be discussed with a healthcare professional.
Patients should not switch medications without professional guidance. Any concerns about efficacy or tolerability are best addressed with the prescriber or pharmacist, who can explain expected timelines and management strategies for side effects.
Take Paxil exactly as prescribed by the prescriber. The product is intended for oral administration, with or without food, according to instructions. Do not alter the dose or frequency without consulting a healthcare professional.
Tablets should be swallowed whole with a drink of water. Orally disintegrating tablets dissolve on the tongue and should be used as directed by the pharmacist or prescriber. Do not crush or chew tablets unless explicitly advised, as this may affect medicine release and absorption.
Consistency supports effectiveness; taking Paxil at roughly the same time each day is advisable. If a dose is missed, follow the professional guidance provided; do not double-dose to make up for a forgotten administration unless advised to do so.
Anticipated effects typically emerge after several weeks of treatment, and improvement may be gradual. If minimal or no improvement is observed after an extended period, consult a prescriber to discuss continuation, dose adjustment, or alternative therapies. Do not discontinue abruptly due to withdrawal risk.
Inform healthcare providers about Paxil use prior to any new medication or procedure, as interactions may occur. A detailed medication history, including over-the-counter products and herbal supplements, supports safe management.
Common adverse effects may include nausea, dry mouth, headaches, sleep disturbances, sweating, and mild sexual dysfunction. Such effects are usually dose-related and tend to abate with ongoing therapy for many patients.
Hyponatremia (low blood sodium) and confusion can occur, particularly in older adults or those with other risk factors. Medical evaluation is advised if symptoms such as severe headache, confusion, or seizures develop. Seek urgent medical help if serious signs arise.
Contraindications include known hypersensitivity to paroxetine or any component of the product. Concomitant use with monoamine oxidase inhibitors (MAO inhibitors) or use within a specified interval after MAO inhibitor therapy is contraindicated due to risk of severe interactions. Check with a clinician before combining Paxil with other antidepressants or serotonergic agents.
Special caution is advised during pregnancy and breastfeeding. The potential risks to the fetus or infant must be weighed against maternal benefits. Involve a healthcare professional when planning pregnancy or during breastfeeding. If pregnancy occurs or is planned, discuss with the prescriber promptly.
Clinical monitoring during initiation and dose changes is recommended, with particular attention to mood changes, suicidality, and emergence of withdrawal symptoms upon tapering. Seek prompt medical advice if new or worsening depressive symptoms or unusual behavioural changes occur.
Several medication interactions require attention to minimize safety risks. Serotonergic drugs, including other SSRIs, SNRIs, triptans, and certain analgesics, may increase the risk of serotonin syndrome when used together with Paxil. This potential interaction warrants professional review before combining therapies.
Nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants, and platelet-inhibiting agents can increase the risk of bleeding when taken with SSRIs. A clinician may weigh this risk and consider alternatives or monitoring strategies. Regular review of all medicines is advised.
MAO inhibitors and certain other antidepressants should not be used concurrently with Paxil. If a switch is planned, an appropriate washout period is generally necessary under medical supervision to reduce the risk of adverse events.
Other interactions may include medications affecting liver enzymes that metabolise Paxil. Dose adjustments or scheduling changes may be required in such cases. Always disclose current medications and supplements to the prescriber or pharmacist.
In older adults, the risk of hyponatremia and confusion may be higher, necessitating closer monitoring. Cognitive or balance concerns should prompt a clinical review of therapy, particularly during initiation.
In patients with liver impairment, Paxil pharmacokinetics may be altered, potentially requiring adjustments or alternative therapies. Hepatic function assessment may be part of ongoing management during prolonged treatment.
Breastfeeding considerations require discussion with a clinician. While Paxil does pass into breast milk, the clinical decision depends on infant well-being and maternal benefit. In some cases, alternative therapies may be preferred.
Access and availability: Paxil is available in Ireland, with options for generic paroxetine formulations. A prescriber determines the most appropriate product formulation and strength for individual needs. Generic substitution policies may vary by jurisdiction and pharmacy practice.
Monitoring involves regular assessment of mood symptoms, anxiety levels, sleep quality, appetite, and functioning. Adherence, adverse effects, and safety signals should be documented and reviewed during follow-up appointments.
Paroxetine is supplied as a generic medicine in many settings, which can influence cost and insurance coverage. Generic options generally provide a broadly equivalent therapeutic effect to brand Paxil when used as directed by a prescriber.
Prescribers consider patient-specific factors, including prior responses to therapy, tolerability of a given preparation, and access to pharmacy services. Some patients may prefer a particular brand due to packaging, tablet size, or consistency of supply. Pharmacists can advise on availability and any substitution rules within the local framework.
Cost considerations may influence adherence; therefore, discussing affordability with a pharmacist can help identify suitable options without compromising efficacy. Always consult the official patient information leaflet for the exact product in use.
Clinical safety and efficacy are maintained when the medication is used as prescribed, with monitoring for adverse effects and drug interactions. When switching between products, professional guidance ensures continuity of care and minimizes withdrawal or rebound symptoms.
In all cases, patient education regarding treatment goals, expected timelines, and safety concerns supports successful therapy. The local healthcare system in Ireland provides resources to assist in decision-making alongside a managing clinician.
The following questions address common considerations when choosing Paxil and comparing it with alternatives. Answers emphasise caution, personalised medical advice, and the importance of professional guidance.
Switching antidepressants should be guided by a prescriber because abrupt changes can cause withdrawal symptoms or symptom relapse. A tapering plan and monitoring schedule are typically required during a switch. Seek professional advice before making changes.
Effectiveness and tolerability vary among individuals. Some patients respond better to Paxil, others to sertraline. A clinician considers history, comorbidities, and side effect profiles when choosing therapy. Personal experience with a previous medication can influence this decision.
Both medicines are effective for depressive symptoms, but differences in tolerability and safety profiles may guide selection. Escitalopram is often associated with a favorable tolerability profile for some patients, whereas Paxil may be chosen for particular anxiety-related symptoms. Professional assessment is essential for a suitable choice.
Switching between Paxil and fluoxetine requires careful planning due to pharmacokinetic differences and withdrawal risks. A washout period or staggered dosing may be advised under medical supervision. Discuss with a prescriber to determine the safest approach.
Generic paroxetine is designed to be therapeutically equivalent to brand Paxil when used as prescribed. Substitution may be allowed by pharmacies, but clinical oversight ensures compatibility with existing treatment plans and monitoring for side effects.
Paroxetine’s particular efficacy profile for anxiety disorders in some individuals, along with past response history and tolerability, can influence the choice. Each patient’s clinical picture guides whether Paxil is the preferred option.
Pregnancy introduces considerations of fetal risk. Paxil may be used in certain circumstances if benefits justify potential risks, but a clinician will assess this carefully. Planning pregnancy should involve a healthcare professional to discuss options and safety.
Alcohol can interact with antidepressants and may worsen side effects or impairment. Limits or avoidance may be advised, depending on individual tolerance and guidance from a clinician. Do not modify intake without medical advice.
Sexual side effects are a known issue with some antidepressants. If such effects are problematic, consult a prescriber which may lead to dose adjustment, switch to a different agent, or adjunctive strategies. Do not stop therapy without professional input.
Yes, some supplements and non-prescription medicines can interact with Paxil or increase adverse effects. Provide a complete list of all products to the prescriber or pharmacist to enable safe co-use. Avoid self-prescribing changes without professional guidance.
Long-term use may be appropriate for some individuals, with periodic review to assess ongoing need, effectiveness, and tolerability. The decision depends on the balance between symptom control and potential risks, as determined by a clinician.
Failure to respond within a typical timeframe should prompt a clinical review. The prescriber may consider dose adjustment, augmentation strategies, or an alternative medication or therapy. Ongoing assessment supports appropriate next steps.
Abrupt discontinuation may cause withdrawal symptoms or rebound symptoms. A gradual taper plan under medical supervision is preferred. If side effects are severe, seek timely medical advice to adjust therapy safely.
Choosing between an SSRI and an SNRI involves evaluating symptom predominance, tolerability, prior response, and potential interactions. A clinician will balance benefits and risks and may propose a trial of one agent with careful monitoring before settling on an ongoing plan.
For detailed information, consult the official patient information leaflet provided with Paxil and any accompanying pharmacovigilance materials. Healthcare professionals, including the prescribing clinician and the pharmacist, can answer questions about individual risk and benefit. In Ireland, local guidelines and hospital or community pharmacy resources can support safe, informed use.
Patients are encouraged to report adverse effects or concerns to a healthcare professional promptly. Seek urgent medical help if sudden severe symptoms or unexpected changes in mood or behaviour occur while taking Paxil.
Educational materials and patient support services may be available through the healthcare system. The aim is to promote safe, effective, and individualised therapy with ongoing professional supervision.
14–21 days. Free from €175.91 .
5–9 days. €26.39
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
